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joined this inter-comparison. Almost every region of Italy was 
represented. In figure 1, the distribution of the PTV gEUD and 
of the MLDeq2Gy PI are shown. The dot line is the minimum 
PI required value; the spread of the data intra-institution and 
inter-institution is visible. The PI related to the rib max dose 
shows a significant correlation (p=0.01) with the use of 
CyberKnife versus Linac or Tomo. Almost all centers have 
values above the minimum required index but all of them, 
except for CyberKnife, show performances below the 
reference one, indicating a weak consideration of this 
constraint. Otherwise, for the PI of spinal cord max dose, all 
center are above the dot line. Any correlation was found 
between performances and the participants expertise or for 
other technical parameters. 
 
 
Figure 1: distribution of gEUD among the centres and of 
MLDeq2Gy performance index. The dot line is the minimum 
required value. 
 
Conclusions: A notable inter-institutional difference in terms 
of gEUD and general planning strategies was found. For a 
multi-institutional study perspective, detailed dose 
specification and planning strategies based on collaboration 
and discussion are mandatory. 
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Purpose/Objective: 4DCT and CBCT imaging in radiotherapy 
delivers a small priming dose, which is ignored in treatment 
planning, despite evidence that the size and sequence of 
partial fractions affects cell survival1,2. The delay between 
imaging and treatment may be minutes or days for CBCT and 
4DCT respectively. There is a trend towards increasing use of 
these imaging modalities as they enable more accurate 
delivery of therapeutic dose. The biological effect of an 
imaging partial fraction in addition to the therapeutic dose 
on cell survival is uncertain. We report here on the effect of 
an imaging dose prior to a therapeutic dose on cell survival in 
two human cancer cell lines and one normal human cell line. 
The effects are examined for current typical imaging dose 
levels and a projection is made of the effects on cell survival 
of an increase in the imaging dose. 
Materials and Methods: In-vitro clonogenic assays were used 
to obtain experimental data for non-small cell lung cancer 
(NCI-H460), melanoma (MM576) and a normal (HUVEC) cell 
lines. The 4DCT was performed on a Toshiba Aquilon CT with 
a Varian RPM motion management system and the CBCT on a 
6MV proton beam from a Varian Novalis linac with a kV-cone 
beam system. The therapeutic dose D2 was delivered after 
time t using the Varian Novalis. An expression for cell survival 
S was derived using the Lea-Catcheside formalism, with and 
without the imaging dose D1. The effect on cell survival of 
increasing the imaging dose to a projected 10, 20 and 50 cGy 
was modelled. 
Results: For the two human cancer cell lines considered in 
this study, D1 (measured to be 0, 0.60cGy [CBCT] or 14.0 cGy 
[4DCT]) given prior to a D2 (0, 2 or 4 Gy), has no measurable 
effect on cell survival, irrespective of the time delay. The 
theoretical analysis confirmed the experimental findings for 
these imaging doses, that an additional partial fraction dose 
from CBCT or 4DCT is not likely to affect tumour control 
significantly as the cell survival was predicted to decrease by 
2-3% for 4DCT. However, if the imaging dose is increased to 
20 and 50 cGy, it is predicted the clonogenic survival would 
decrease by 6 and 15% respectively for the cancer cell lines. 
This decrease was predicted to be smaller for the normal cell 
line (4 and 6% for 20 and 50 cGy respectively). 
Conclusions: This study indicates that, at the current dose 
levels, it is not necessary to consider the imaging dose from 
4DCT or CBCT in the planning of radiotherapy treatment. 
However, if the imaging dose is increased then imaging dose 
may need to be included in treatment planning. 
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Purpose/Objective: While conventionally fractionated 
radiotherapy (CFRT) has proven ineffective in curing non-
small-cell lung cancer (NSCLC), promising results have been 
obtained with stereotactic body radiotherapy (SBRT) 
employing few high-dose fractions. Extreme 
hypofractionation might however compromise the treatment 
outcome in hypoxic tumours given the reduced possibility for 
reoxygention between fractions. An alternative approach 
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could involve schedules employing fewer fractions than CFRT, 
but more than in a typical SBRT treatment while partly 
escalating the fractional dose. It was the purpose of this 
study to investigate heterogeneous fractionation patterns 
with respect to the dose per fraction, taking into account the 
spatial and dynamic aspects of the tumour oxygenation and 
the effect of accelerated repopulation of tumour cells in 
treatments extending over several weeks. 
Materials and Methods: Three-dimensional in silico tumours 
with heterogeneous oxygenation were simulated based on 
previous calculations from intervessel distance distributions. 
Homogeneous dose delivery was simulated employing 2 Gy 
per fraction as baseline and partly escalating the dose to 3 
and 4 Gy per fraction corresponding to fractions delivered 
prior to or directly following a short interruption of the 
treatment as represented by the weekends. Survival was 
assessed on voxel level with the linear-quadratic (LQ) model 
taking into account the dose-modifying effect of the 
oxygenation. The effect of accelerated repopulation was 
incorporated assuming a kick-off time of 14 days and a 
potential doubling time of 5 days for NSCLC. Local control 
was evaluated as tumour control probability (TCP) through a 
Poisson-based model and dose-response curves were 
generated by systematically varying the total dose. 
Results: For tumours with a negligible level of spread-out 
hypoxia (left panel of Figure 1) and assuming that 
accelerated repopulation starts after two weeks, partly 
increasing the fractional dose could substantially improve 
local control even if no reoxygenation takes place. If however 
the effects of repopulation are neglected and the hypoxia is 
geometrically concentrated instead of being spread out 
throughout the tumour, the impact of reoxygenation is far 
more important than partly escalating the fractional dose, 
even for small hypoxic fractions (right panel of Figure 1). 
 
 
Conclusions: Heterogeneous fractionation might ensure high 
levels of control in well-oxygenated tumours even when 
inter-fraction reoxygenation cannot be assumed. For tumours 
with more concentrated hypoxia, moderately heterogeneous 
fractionation patterns cannot counteract the increased 
radioresistance of tumour hypoxia.  
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Purpose/Objective: Dose given to the tumour in patients 
with locally-advanced pancreatic cancer (LAPC) is limited by 
normal tissue toxicity in the gastrointestinal tract. The close 
proximity of the duodenum to the target volume therefore 
makes studying the link between duodenal dose and 
treatment outcome of interest. This study investigates the 
effect of changes in size and position of the duodenum 
throughout treatment on dosimetric parameters. 
Materials and Methods: Three patients from the ARCII trial 
(EudraCT 2008-006302-42) treating LAPC with 
chemoradiotherapy were chosen for this study. CBCTs from 
fractions 6, 12, 18 and 24 were fused with the planning CT 
using a bony and soft tissue match. The duodenum was 
contoured on the planning CT and each CBCT by a single 
physician. The contours were copied to the ARCII trial 3D 
conformal plan prescribing 50.4Gy in 28 fractions to the PTV 
with a subsequent boost of 9Gy in 5 fractions to a smaller 
PTV for a total of 59.4Gy. The total volume of the duodenum 
and the percentage of the duodenum outside of the PTV (% 
out) were recorded together with V35 and V55 from the 
duodenum dose surface histograms (DSHs). 
Results: The volume of the duodenum on the planning CT and 
the range of duodenum volumes over the 4 CBCT contours 
were 86.6cm3 (56.7 - 71.9), 41.6cm3 (45.9 - 80.6) and 
93.1cm3 (76.7 - 132.7) for patients 1, 2 and 3 respectively. 
Figure 1 shows large interfraction variation in the volume of 
the duodenum. There is also variation in the percentage of 
the duodenum located outside the PTV. It is also seen that as 
more of the duodenum is found outside the PTV, the dose 
volume metrics of the duodenum are reduced. There is no 
such link to absolute volume change. 
